A Study of SI-6603 in Patients With Lumbar Disc Herniation

Trial Profile

A Study of SI-6603 in Patients With Lumbar Disc Herniation

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Condoliase (Primary)
  • Indications Intervertebral disc displacement
  • Focus Registrational; Therapeutic Use
  • Sponsors Seikagaku Corporation
  • Most Recent Events

    • 07 Nov 2017 Primary endpoint (Leg pain) has not been met, according to a Seikagaku Corporation media release.
    • 07 Nov 2017 According to a Seikagaku Corporation media release, status changed from active, no longer recruiting to completed.
    • 25 Nov 2015 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top